targeted oncology Archives -

Tagrisso paired with Hutchmed drug clears lung cancer test

Phil Taylor AstraZeneca, HutchMed, Non-small cell lung cancer, Oncology, Orpathys, Tagrisso, targeted oncology 0 Comment

EGFR inhibitors like AstraZeneca’s Tagrisso have been hugely successful in treating EGFR-positive lung cancer, but the durability of

Tagrisso paired with Hutchmed drug clears lung cancer test

https://pharmaphorum.com/news/tagrisso-paired-with-hutchmed-drug-clears-lung-cancer-test/

Radiology technician examens mammography test

News/ News/ News/ Oncology/ Sales and Marketing

AZ, Merck get EU nod for Lynparza as adjuvant breast cancer therapy

Phil Taylor adjuvant, AstraZeneca, breast cancer, EU, Lynparza, Merck & Co, Oncology, targeted oncology 0 Comment

The European Commission has cleared AstraZeneca and Merck & Co’s Lynparza as an adjuvant treatment for breast cancer,

AZ, Merck get EU nod for Lynparza as adjuvant breast cancer therapy

https://pharmaphorum.com/news/az-merck-get-eu-nod-for-lynparza-as-adjuvant-breast-cancer-therapy/

News/ News/ News/ Oncology/ Sales and Marketing

FDA clears new first-line use for Servier’s Tibsovo in AML

Phil Taylor acute myeloid leukaemia, Oncology, Servier, targeted oncology, Tibsovo 0 Comment

Servier is on course to get a return on its $1.8 billion takeover of Agios Pharma’s oncology business

FDA clears new first-line use for Servier’s Tibsovo in AML

https://pharmaphorum.com/news/fda-clears-new-first-line-use-for-serviers-tibsovo-in-aml/

News/ News/ Oncology

AZ, Merck get FDA okay for Lynparza as adjuvant breast cancer therapy

Phil Taylor AstraZeneca, BRCA, breast cancer, Merck & Co, Oncology, PARP inhibitor, regulatory approval, targeted oncology 0 Comment

The FDA has cleared AstraZeneca and Merck & Co’s Lynparza as an adjuvant or neoadjuvant treatment for breast

AZ, Merck get FDA okay for Lynparza as adjuvant breast cancer therapy

https://pharmaphorum.com/news/az-merck-get-fda-okay-for-lynparza-as-adjuvant-breast-cancer-therapy/

News/ News/ Oncology

Amgen grabs EU approval for pathfinder KRAS drug Lumykras

Phil Taylor Amgen, KRAS, Lumakras, Lumykras, Non-small cell lung cancer, Oncology, targeted oncology 0 Comment

Amgen now has regulatory approval on both sides of the Atlantic for Lumykras, the culmination of many years

Amgen grabs EU approval for pathfinder KRAS drug Lumykras

https://pharmaphorum.com/news/amgen-grabs-eu-approval-for-pathfinder-kras-drug-lumykras/

News/ News/ Oncology

ASH: Servier’s Tibsovo poised for first-line used in AML

Phil Taylor acute myeloid leukaemia, Oncology, Servier, targeted oncology, Tibsovo 0 Comment

Servier has revealed the full data from its phase 3 trial of Tibsovo as a first-line treatment for

ASH: Servier’s Tibsovo poised for first-line used in AML

https://pharmaphorum.com/news/ash-serviers-tibsovo-poised-for-first-line-used-in-aml/

Market Access/ News/ News

Takeda gets a win for its Wave1 pipeline, as Exkivity nabs FDA approval

Phil Taylor EGFR, Exkivity, fda, NSCLC, Oncology, regulatory approval, Takeda, targeted oncology 0 Comment

Takeda has had a run of bad luck with its Wave1 pipeline of new drug candidates of late,

Takeda gets a win for its Wave1 pipeline, as Exkivity nabs FDA approval

https://pharmaphorum.com/news/takeda-gets-a-win-for-its-wave1-pipeline-as-exkivity-nabs-fda-approval/

News/ News/ Oncology

Servier gets a win for cancer drug Tibsovo, bought in $1.8bn Agios deal

Phil Taylor acute myeloid leukaemia, Agios, haemotology, Oncology, Servier, targeted oncology 0 Comment

Just three months after completing its $1.8 billion takeover of Agios’ oncology pipeline, Servier has reported positive results

Servier gets a win for cancer drug Tibsovo, bought in $1.8bn Agios deal

https://pharmaphorum.com/news/servier-gets-a-win-for-cancer-drug-tibsovo-bought-in-1-8bn-agios-deal/

Market Access/ News/ News

NICE changes its mind on rare bile duct cancer drug from Incyte

Phil Taylor cholangiocarcinoma, HEOR, Incyte, NICE, Oncology, Pemazyre, pemigatinib, targeted oncology 0 Comment

Incyte’s Pemazyre has become the first targeted therapy available for NHS patients with cholangiocarcinoma or bile duct cancer,

NICE changes its mind on rare bile duct cancer drug from Incyte

https://pharmaphorum.com/news/nice-changes-its-mind-on-rare-bile-duct-cancer-drug-from-incyte/

Trending

targeted oncology

Login